Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives

Table 2 Major heart failure trials with sodium glucose cotransporter 2 inhibitors

Trial and medication name	Primary endpoint	Median follow-up	Outcomes
HFrEF
DAPA-HF (dapagliflozin)	Primary composite outcome: Worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for HF) + cardiovascular death	18 months	Reduction in the primary composite outcome by 24%
EMPEROR-reduced (empagliflozin)	Primary composite outcome: Hospitalisation for heart failure + cardiovascular death	16 months	Reduction in the primary composite outcome by 22%
HFpEF
EMPEROR-preserved (empagliflozin)	Primary composite outcome: Hospitalisation for heart failure + cardiovascular death	26 months	19% reduction in the primary composite outcome
DELIVER (dapagliflozin)	Primary composite outcome: Worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for HF) + cardiovascular death	28 months	18% reduction in the primary composite endpoint

HFrEF: Heart failure with reduced ejection fraction; HFpEF: Heart failure with preserved ejection fraction; HR: Hazard ratio.